Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1923]

Immune checkpoint based approaches in AML and MDS

Dr Naval Daver - University of Texas MD Anderson Cancer Center, Houston, USA

Immune checkpoint based approaches in AML and MDS ( Dr Naval Daver - University of Texas MD Anderson Cancer Center, Houston, USA )

CARTs for the treatment of T-cell malignancies

Dr John DiPersio - Siteman Cancer Center, St. Louis, USA

CARTs for the treatment of T-cell malignancies ( Dr John DiPersio - Siteman Cancer Center, St. Louis, USA )

COVID-19: Should we continue using immunomodulatory drugs to treat our patients?

Dr Sophie Papa - King's College London, London, UK

COVID-19: Should we continue using immunomodulatory drugs to treat our patients? ( Dr Sophie Papa - King's College London, London, UK )

Management of mutation-negative NSCLC

Dr Vijay Patil - Tata Medical Center, Kolkata, India

Management of mutation-negative NSCLC ( Dr Vijay Patil - Tata Medical Center, Kolkata, India )

Management of advanced cervical cancer

Dr Avinash Pandey - State Cancer Institute, Patna, India

Management of advanced cervical cancer ( Dr Avinash Pandey - State Cancer Institute, Patna, India )

Working up metastatic NSCLC

Dr Depak Dabkara - Tata Medical Center, Kolkata, India

Working up metastatic NSCLC ( Dr Depak Dabkara - Tata Medical Center, Kolkata, India )

EV-103: Enfortumab vedotin plus pembrolizumab for locally advanced or...

Dr Jonathan Rosenberg - Memorial Sloan Kettering Cancer Center, New York, USA

EV-103: Enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma ( Dr Jonathan Rosenberg - Memorial Sloan Kettering Cancer Center, New York, USA )

KEYNOTE 199 cohorts 4 & 5: Enzalutamide and pembrolizumab for mCRPC

Dr Julie Graff - Oregon Health & Science University, Portland, USA

KEYNOTE 199 cohorts 4 & 5: Enzalutamide and pembrolizumab for mCRPC ( Dr Julie Graff - Oregon Health & Science University, Portland, USA )

BCG dosing for bladder cancer: Standard frequency schedule correct

Prof Oliver Grimm - Universitätsklinikum Jena, Jena, Germany

BCG dosing for bladder cancer: Standard frequency schedule correct ( Prof Oliver Grimm - Universitätsklinikum Jena, Jena, Germany )

RADVAX: Nivolumab / ipilimumab with SBRT for metastatic renal cell carcinoma

Dr Hans Hammers - UT Southwestern Medical Center, Dallas, USA

RADVAX: Nivolumab / ipilimumab with SBRT for metastatic renal cell carcinoma ( Dr Hans Hammers - UT Southwestern Medical Center, Dallas, USA )

Integrative molecular characterisation of S/R RCC to reveal determinants of...

Dr Ziad Bakouny - Dana-Farber Cancer Institute, Boston, USA

Integrative molecular characterisation of S/R RCC to reveal determinants of poor prognosis and response to ICIs ( Dr Ziad Bakouny - Dana-Farber Cancer Institute, Boston, USA )

Cytoreductive nephrectomy for mRCC treated with immune checkpoint inhibitors or...

Dr Ziad Bakouny - Dana-Farber Cancer Institute, Boston, USA

Cytoreductive nephrectomy for mRCC treated with immune checkpoint inhibitors or targeted therapy ( Dr Ziad Bakouny - Dana-Farber Cancer Institute, Boston, USA )

More from ecancer